CompletedPHASE1, PHASE2NCT00514046

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Studying Medullary thyroid carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Brigitte C Widemann, M.D., Pharm.D
National Cancer Institute (NCI)
Intervention
Vandetanib(drug)
Enrollment
17 enrolled
Eligibility
5-18 years · All sexes
Timeline
20072020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00514046 on ClinicalTrials.gov

Other trials for Medullary thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Medullary thyroid carcinoma

← Back to all trials